Once-a-Week Insulin in India: How Awiqli Cuts 365 Injections to Just 52

India has entered a new chapter in diabetes treatment with the launch of Awiqli (insulin icodec), a once-weekly basal insulin developed by Novo Nordisk. Instead of requiring a basal insulin injection every day, the new formulation is designed to provide insulin coverage through a single injection each week.

That changes one of the most repetitive parts of insulin therapy: the number of injections. For a regimen that previously required one basal injection every day, the annual count can fall from 365 injections to 52.

The development is significant not because insulin itself is new, but because scientists have redesigned how long the medicine can remain active inside the body. Awiqli uses insulin icodec, a specially engineered insulin molecule designed to provide a prolonged and relatively stable insulin effect over approximately one week.

The launch in India in July 2026 makes the country one of the early markets to receive this technology and represents an important development in the science of long-acting medicines.

Why Weekly Insulin Is Such a Major Change

Insulin plays a fundamental role in controlling blood glucose. It helps glucose move from the bloodstream into cells, where it can be used for energy.

People with Type 1 diabetes require insulin because their bodies produce little or no insulin of their own. Many people with Type 2 diabetes may also eventually require insulin when their natural insulin production is insufficient to maintain adequate glucose control.

Traditional basal insulin therapy often involves an injection once a day. Depending on an individual’s treatment plan, additional insulin may also be required around meals.

That means insulin treatment can become a daily routine involving medication, injection equipment, blood-glucose monitoring and careful scheduling.

A once-weekly basal insulin does not eliminate all of those requirements, but it can substantially reduce the frequency of basal insulin injections.

Instead of remembering a basal injection every day, an eligible patient may have a weekly schedule for the basal component of treatment.

That is the central innovation behind Awiqli.

The Science Behind Insulin Icodec

The interesting scientific feature of Awiqli is the molecule itself.

Insulin icodec has been engineered to remain in the body for a much longer period than conventional shorter-acting insulin formulations. One mechanism contributing to its extended action involves its ability to bind to albumin, a major protein circulating in the blood.

This creates a kind of circulating reservoir.

Rather than releasing its insulin activity rapidly and disappearing from the body, insulin icodec is designed to provide a sustained insulin effect over the week. An endocrinology expert interviewed by The Week explained that the albumin-binding mechanism helps create a steady, inactive depot from which the insulin can gradually become active.

In simple terms, scientists have changed the pharmacokinetics of insulin — the way a medicine moves through and behaves inside the body.

This is a major area of modern pharmaceutical science.

The challenge is not merely creating a drug that works. Scientists also have to determine how quickly it enters the bloodstream, how long it remains available, how it is cleared from the body and how consistently it produces its intended effect.

A weekly medicine requires especially careful control of these characteristics.

From 365 Injections to 52

The most immediately understandable advantage is the reduction in injection frequency.

A daily basal insulin schedule can involve approximately:

1 injection × 365 days = 365 injections per year

With a weekly basal insulin:

1 injection × 52 weeks = 52 injections per year

That means 313 fewer basal insulin injections in a year.

The change may appear simple mathematically, but it could have a meaningful effect on the everyday experience of treatment.

People who dislike needles, have difficulty maintaining daily medication schedules, travel frequently or depend on caregivers for injections may find a weekly routine easier to manage.

Doctors and researchers have therefore been interested in whether reducing treatment burden can also improve treatment adherence.

India Today reported that reducing the injection schedule could help patients and caregivers manage diabetes treatment more easily, although weekly insulin remains part of a broader diabetes-management plan rather than a cure.

It Is Not a Cure for Diabetes

The phrase “once-a-week insulin” can easily create a misunderstanding.

Awiqli is not a cure for diabetes.

It is a different way of delivering basal insulin.

Patients still need appropriate medical supervision and glucose management. For people with Type 1 diabetes, basal insulin also does not remove the need for mealtime insulin. The weekly formulation is intended to replace the daily basal component, not necessarily every insulin dose a person may require.

The Economic Times similarly reported that doctors view the medicine as an additional treatment option rather than a universal replacement for all daily insulin regimens.

This distinction is particularly important because diabetes is not one single condition with one identical treatment strategy.

Treatment depends on the type of diabetes, glucose levels, insulin production, other medicines, diet, physical activity and many other individual factors.

Why Injection Frequency Matters

The science of diabetes treatment is not only about lowering glucose.

Researchers also study treatment adherence — whether patients are able and willing to follow the prescribed treatment schedule over the long term.

A medication can work extremely well in clinical trials, but if people frequently miss doses in real life, the potential benefit may not be fully achieved.

Daily injections can create practical challenges.

A person may be travelling, working long hours, attending an event or simply forget a dose. Some people also experience anxiety around needles.

For caregivers, the responsibility can be even more complicated.

If an older person cannot administer insulin independently, a family member or caregiver may need to help every day. Moving the basal injection schedule from daily to weekly could reduce the number of occasions when another person has to assist.

This is one reason the innovation is being viewed as more than a pharmaceutical modification.

It is also an attempt to redesign the patient experience of insulin therapy.

India’s Growing Need for Better Diabetes Care

The launch is particularly significant in India because the country has a very large diabetes population.

Reuters reported that India has more than 101 million people with diabetes and around 136 million people classified as having prediabetes, while approximately 6 million people currently use insulin therapy.

These numbers demonstrate why improvements in diabetes treatment can have enormous implications.

Even a relatively small improvement in treatment convenience can potentially affect millions of people if it is clinically appropriate, affordable and accessible.

The challenge, however, is not simply making innovative medicines available.

Healthcare systems also have to ensure proper diagnosis, physician supervision, affordability, education and access.

How Much Does Awiqli Cost in India?

At launch, reports put the price of Awiqli at around ₹261 for a 70-unit weekly dose, while the pre-filled pen presentations were reported at approximately ₹2,611 for the 1 ml pen and ₹7,833–₹7,883 for the larger 3 ml presentation, depending on the reported source and pack details.

The actual cost for an individual patient can vary depending on prescribed dosage, pack size and other factors.

Cost is important because affordability remains one of the biggest considerations in long-term diabetes management.

A technology that reduces injections but becomes financially inaccessible to patients would have a much smaller public-health impact.

The long-term significance of Awiqli in India will therefore depend not only on its pharmacological advantages but also on availability and affordability.

What Clinical Research Has Shown

The development of insulin icodec has been supported by clinical research examining its ability to provide glucose control while reducing injection frequency.

According to information reported at the Indian launch, the ONWARDS clinical programme evaluated insulin icodec in different diabetes-treatment settings. Novo Nordisk reported that the programme demonstrated improvements in measures including HbA1c and time in range in certain comparisons with daily basal insulin.

HbA1c provides an estimate of average blood-glucose levels over a longer period, while time in range describes how much time glucose levels remain within a specified target range.

These measurements are important because diabetes control cannot be evaluated simply by looking at whether someone has taken their medication.

Researchers need to examine how consistently glucose levels are controlled and whether treatment causes unwanted episodes such as hypoglycaemia.

Why a Weekly Drug Requires Careful Engineering

Creating a medicine that lasts for a week presents a different scientific challenge from creating one that lasts for a few hours.

The drug must remain sufficiently stable.

Its activity must be predictable.

The body must receive an appropriate amount of active insulin over time.

And the medicine must avoid producing excessive peaks that could increase the risk of dangerously low blood glucose.

This is where pharmaceutical engineering becomes particularly important.

Scientists can modify the molecular structure of a medicine to alter its absorption, distribution, binding characteristics and clearance.

In the case of insulin icodec, the goal was to create a formulation that can provide prolonged basal insulin action while maintaining a manageable dosing schedule.

The result is an example of how modern medicine increasingly focuses not only on what a drug does, but also on how the body receives it.

What Changes for Patients?

For an eligible patient whose doctor switches the basal insulin regimen to a once-weekly formulation, the most obvious change is the calendar.

Instead of thinking about the basal insulin dose every day, the patient follows a weekly schedule.

That could make treatment easier to integrate into work, travel and family routines.

It may also reduce the psychological burden associated with repeated injections.

However, patients should not interpret “once a week” as meaning they can independently change their insulin schedule.

Insulin is a powerful medicine, and changes in insulin type, dose or timing require medical supervision.

A weekly formulation also does not mean that glucose monitoring, dietary management or other prescribed medicines can simply be abandoned.

A New Direction for Long-Acting Medicines

The importance of Awiqli extends beyond diabetes.

Pharmaceutical researchers have spent decades trying to develop medicines that require fewer doses while maintaining therapeutic effectiveness.

The reason is straightforward: less frequent dosing can make long-term treatment easier to manage.

The same concept appears across medicine.

Scientists have developed extended-release tablets, long-acting injections, implants and drug-delivery systems designed to keep medicines active for longer periods.

Weekly insulin is another example of this broader scientific movement.

Instead of repeatedly administering a medicine to maintain its effect, researchers attempt to create a formulation capable of maintaining the required biological activity over a much longer period.

India Becomes Part of a Global Shift

India’s launch of Awiqli places the country among the early markets adopting once-weekly basal insulin.

Reports said India became the seventh market where the therapy was launched.

That is significant because India is not only a major diabetes market but also an important pharmaceutical and healthcare market.

The arrival of long-acting insulin technology could stimulate greater discussion around treatment adherence, patient convenience and the future of diabetes care.

But the real test will come over time.

Researchers and healthcare professionals will continue to observe how patients use the therapy in everyday life, how well they maintain glucose control, how affordable the treatment is and which patient groups benefit most.

The Future of Insulin May Be Less About Needles

For more than a century, insulin has transformed diabetes from a frequently fatal disease into a condition that can be managed with appropriate treatment.

The next stage of insulin innovation is increasingly focused on making that treatment easier to live with.

The once-weekly approach does not change the fundamental biology of diabetes. It does not eliminate the need for medical care. And it is not appropriate for every person using insulin.

What it does demonstrate is how far drug-delivery science has advanced.

Scientists have taken a hormone that historically had to be administered repeatedly and engineered a version capable of providing basal insulin coverage over an entire week.

For eligible adults in India, that means a potential shift from 365 basal injections a year to 52.

That is more than a change in numbers.

It represents a broader direction in medical science: making treatments last longer, work more predictably and fit more naturally into people’s lives.

The future of diabetes care may therefore not be defined only by discovering new medicines.

It may also be defined by finding smarter ways to deliver the medicines that already save lives.